

PUREGENE BIOTECH LIMITED

CIN: U01222MP1999PLC013303

ANNUAL REPORT 2016-17

PUREGENE BIOTECH LIMITED

(CIN: U01222MP1999PLC013303)

Regd. Office: 1-B, Vikas Rekha Complex, Tower Square, Indore (M.P.)-452001

E-mail: simranfarmscs@gmail.com; Ph.: 0731-4255900

BOARD OF DIRECTORS

Mr. Harender Singh Bhatia

Director

Mr. Kawaljeet Singh Bhatia

Director

Mr. Gurmeet Singh Bhatia

Director

STATUTORY AUDITORS

M/s Khandelwal Kakani & Co.

Chartered Accountants

Indore (M.P.)

REGISTERED OFFICE

PUREGENE BIOTECH LIMITED

CIN: U01222MP1999PLC013303

Regd. Office: 1-B, Vikas Rekha Complex,

Tower Square, Indore 452001(M.P)

Ph.: 0731-4255900, Fax: 0731-4255949

E-mail: simranfarmscs@gmail.com,

LEGAL ADVISORES

Mr. Pankaj Joshi

Mr. L.D. Joshi

(Tax Consultants & Advocates)

PUREGENE BIOTECH LIMITED

(CIN: U01222MP1999PLC013303)

Regd. Office: 1-B, Vikas Rekha Complex, Tower Square, Indore (M.P.)-452001

E-mail: simranfarmscs@gmail.com; Ph.: 0731-4255900

BOARD'S REPORT

To

The Members,
PUREGENE BIOTECH LIMITED
Indore (M.P)

Your directors are pleased to present the 18th Annual Report together with the Audited Financial Statement for the year ended 31st March, 2017.

1. STATE OF AFFAIRS, FINANCIAL PERFORMANCE AND FUTURE OUTLOOK:

1.1 FINANCIAL HIGHLIGHTS AND SUMMARY

During the year under review, performance of your company is as under:

(Rs. in Lakhs except EPS)

Particulars	Year Ended	
	31 st Mar, 2017	31 st Mar, 2016
Total Revenue	54.00	54.00
Total Expenditure	29.03	28.80
Profit/(Loss) before depreciation and tax	24.97	25.20
Less : Depreciation	8.88	9.01
Profit/(Loss) before tax	16.09	16.19
Tax Expenses:		
Less : Current Tax	6.13	5.96
Less : Deferred Tax	0.00	0.00
Add : MAT Credit	0.00	0.00
Net Profit/(Loss) for the year	9.96	10.23
Appropriation for Profit	49.71	39.75
Paid up Equity Share Capital	144.67	144.67
Earnings per share (Rs. 10/- each) Basic & Diluted	0.69	0.71

During the year under review, the Company has made total income of Rs. 54.00 lacs and earned net profit of Rs. 9.96 lakhs in comparison to previous year in which company made total income of Rs. 54.00 lacs and earned net profit of Rs. 10.23 lacs.

1.2 OPERATIONS AND FUTURE OUTLOOK

Presently, the Company does not have any substantial business activities and income is earned from rearing and growing charges from its holding company only. However, directors are hopeful that business activities may start in coming years looking into the positive trend in poultry business.

1.3 CHANGE IN NATURE OF BUSINESS

During the year, there was no change in business activity of the company.

1.4 CHANGES IN SHARE CAPITAL

The paid up Equity Share Capital of the Company as at March 31, 2017 stood at Rs. 144.67 lakhs. During the Financial Year 2016-17, there was no change in capital structure of the company. The Company currently has no outstanding shares issued with differential rights, sweat equity or ESOS.

1.5 REVISION OF ANNUAL FINANCIAL STATEMENTS

There was no such case of revision in financial statements during the year.

2. EXTRACT OF ANNUAL RETURN

The extract of Annual Return as prescribed in Form MGT-9 required under section 92 of the Companies Act, 2013 is included in this report as **Annexure I**.

3. NUMBER OF MEETINGS OF THE BOARD

During the Financial Year 2016-17, the Board of the directors duly met 5 times on 30.05.2016, 11.08.2016, 31.10.2016, 10.11.2016 and 13.02.2017 respectively for which proper notices for meeting were given and the proceedings were properly recorded. Draft Minutes of Board Meeting were circulated to members of the Board for their comments. Thereafter, signed copies of minutes were also circulated to Board member for confirmation of the same. Details of attendances are as under:

Sr. No.	Director	No. of Board Meetings held during the year		Attendance at the previous Annual General Meeting
		Held	Attended	
1	Mr. Harender Singh Bhatia	5	5	Yes
2	Mr. Kawaljeet Singh Bhatia	5	5	Yes
3	Mr. Gurmeet Singh Bhatia	5	5	No

DETAILS OF COMMITTEE MEETING: There is no committee constituted by the company during the year under review.

4. DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to the provisions of Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirm that:

- a) in the preparation of the annual accounts for the financial year ended 31st March, 2017, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;
- b) the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2017 and of the profit of the Company for year ended on that date;
- c) the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) the annual accounts have been prepared on a going concern basis;
- e) the directors had laid down internal financial controls to be followed by company and that such internal financial controls are adequate and were operating effectively;

- f) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

5. REPORTING OF FRAUD BY STATUTORY AUDITORS

During the year under review, there was no fraud in the Company; hence no reporting was made by Statutory Auditors of the Company under sub-section (12) of Section 143 of Companies Act, 2013.

6. APPOINTMENT AND STATEMENT ON DECLARATION BY INDEPENDENT DIRECTOR:

There is no requirement to appoint any Independent Directors pursuant to the provision of Section 149(6) read with 149 (10) of Companies Act, 2013.

7. NOMINATION AND REMUNERATION COMMITTEE AND STAKEHOLDERS' RELATIONSHIP COMMITTEE:

There is no requirement to constitute any Nomination & Remuneration Committee under Section 178(1) of the Companies Act, 2013 and Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Stakeholders' Relationship Committee under Section 178(5) of the Companies Act, 2013.

8. STATUTORY AUDITORS:

Pursuant to the provisions of section 139 of the Act and the rules framed thereafter, M/s. Khandelwal Kakani & Co, Chartered Accountants (FRN: 001311C), were appointed as statutory auditors of the Company from the conclusion of the 15th Annual General Meeting (AGM) of the Company held on 30.09.2014 till the conclusion of the 20th AGM to be held in the year 2019, subject to ratification of their appointment at every AGM.

M/s. Khandelwal Kakani & Co, Chartered Accountants (FRN: 001311C) who are Statutory Auditors of the Company hold office up to the forthcoming Annual General Meeting and are recommended for ratification for the financial year 2017-18. As required under the provisions of Section 139 of the Companies Act, 2013, the Company has obtained written confirmation from M/s. Khandelwal Kakani & Co, Chartered Accountants that their appointment, if made, would be in conformity with the limits specified in the said Section.

9. EXPLANATION TO AUDITOR'S REMARK:

The Auditors in their report have referred to the notes forming part of the Accounts which are self-explanatory and does contain any qualification, reservation or adverse remark or disclaimer and do not require any further explanation/ clarification by the Board of Directors.

10. COST RECORD AND/OR COST AUDIT

Your company does not fall within the provisions of Section 148 of Companies Act, 2013 read with the Companies (Cost Records & Audit) Rules, 2014, therefore no such records required to be maintained.

11. SECRETARIAL AUDIT REPORT

Provisions of Section 204 of the Companies Act, 2013 read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, are not applicable to the Company.

12. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS BY COMPANY

Your Company has not provided loans/guarantees and not made any investments in terms of Section 186 of the Companies Act, 2013, if any.

13. RELATED PARTY TRANSACTION:

All related party transactions that were entered into during the financial year were on arm's length basis and in the ordinary course of business. Further, a disclosure as required under Section 134(3)(h) of the Companies Act, 2013 and the Rule 8(2) of the Companies (Accounts) Rules, 2014 being enclosed in Form AOC-2 as **Annexure II** with the Board's Report.

14. AMOUNT TRANSFER TO RESERVE:

During the year under review, your Company has not transferred any amount to reserve.

15. DIVIDEND:

To conserve the resources and plough back of profit, your directors do not recommend any dividend for the year under review.

16. MATERIAL CHANGES & COMMITMENTS, IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

No material changes and commitments affecting the financial position of the company have occurred during the financial year to which the financial statements relate and at the date of this Board's Report.

17. PARTICULARS OF CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

17.1 CONSERVATION OF ENERGY

a. The steps taken or impact on conservation of energy:-

The operations of the Company are not power intensive as the Company doesn't possess the manufacturing activities; hence this clause is not applicable to the company.

b. The steps taken by the company for utilizing alternate sources of energy:- NIL

c. The capital investment on energy conservation equipments:- NIL

17.2 TECHNOLOGY ABSORPTION

a. The effort made towards technology absorption-

No specific activities have been done by the Company.

b. The benefits derived like product improvement, cost reduction, product development or import substitution-

No specific activity has been done by the Company

c. In case of imported technology (imported during the last three years reckoned from the beginning of the financial year):- NA

d. The expenditure incurred on Research & Development.- NIL

17.3 FOREIGN EXCHANGE EARNINGS AND OUTGO

There were no Foreign Exchange earnings and outgoings taken place during the financial year as required by Companies (Accounts) Rules, 2014.

18. STATEMENT INDICATING DEVELOPMENT & IMPLEMENTATION OF RISK MANAGEMENT POLICY:

The Board of Directors of the Company state that risk associated in the ordinary course of business is duly taken care by the Board while taking business decisions. Further, the Company need not required to formulate any specified risk management policy.

19. CORPORATE SOCIAL RESPONSIBILITY:

The Company is not required to provide statement on Corporate Social Responsibility as per Section 134(3)(o) of the Companies Act, 2013 as the Company does not fall under the criteria provided under Section 135 (1) of Companies Act, 2013, therefore no such committee was constituted.

20. ANNUAL EVALUATION OF PERFORMANCE OF BOARD:

The Company was not required to carry formal annual evaluation by the Board of its own performance and individual directors pursuant to Section 134(3)(p) of the Companies Act, 2013 and Rule 8(4) of the Companies (Accounts) Rules, 2014.

21. DIRECTORS & KEY MANAGERIAL PERSONNEL:

During the year, there was no change in the constitution of the Board of Directors of the Company. In view of the status of the Company, it is not required to appoint any key managerial personnel under the provisions of Section 203 of the Companies Act, 2013 and rules made there under.

Further, pursuant to the provisions of Section 152 of the Companies Act, 2013, Mr. Kawaljeet Singh Bhatia (DIN:00401827), Director of the Company retires by rotation at the ensuing Annual General Meeting and being eligible, offers himself for re-appointment.

DISQUALIFICATIONS OF DIRECTORS

During the year, declarations received from the Directors of the Company pursuant to Section 164 of the Companies Act, 2013. The Board appraised the same and found that none of the director is disqualified for holding office as director.

22. SUBSIDIARY, ASSOCIATE COMPANIES OR JOINT VENTURE:

The Company does not have any subsidiary company or associate company or any joint venture company. However company is subsidiary company of Simran Farms Limited (CIN: L01222MP1984PLC002627).

23. DEPOSITS:

During the year, the Company has not accepted any deposits, within the meaning of Section 73 of the Companies Act, 2013, read with the Companies (Acceptance of Deposits) Rules, 2014.

24. DISCLOSURE OF UNSECURED LOAN RECEIVED FROM DIRECTORS:

Pursuant to Section 2(31) Read with Rule 2(1)(viii) of Companies (Acceptance of Deposits) Rules, 2014, (including any statutory modification or re-enactment thereof for the time being in force), the Company has not received any unsecured loan from director during the financial year.

25. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:

There are no significant material orders passed by the Regulators/Courts/Tribunals impacting the going concern status of the Company and its future operations.

26. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:

The internal control system with respect to financial statement and there adequacy has been duly taken care by the Board of Directors of the Company and it has also been reviewed by the Statutory Auditors. The internal controls exist in the system and that sufficient measures are taken to update the internal control system, as and when needed. The system also ensures that all transaction are appropriately authorized, recorded and reported as and when required.

27. AUDIT COMMITTEE:

Provisions of Section 177(1) of Companies Act, 2013 is not applicable to the Company; hence there is no requirement for constituting an Audit Committee.

28. ESTABLISHMENT OF VIGIL MECHANISM:

Provisions of Section 177(10) of Companies Act, 2013 for establishment of Vigil Mechanism are not applicable to the Company. However, Management of the Company has established the mechanism which provides for the adequate safeguards against victimization.

29. COMMISSION RECEIVED BY DIRECTORS FROM HOLDING/SUBSIDIARY:

During the year under, review all the directors of the company were in receipt of the remuneration from holding company of the company as provided under section 197 (14) of Companies Act, 2013.

30. PARTICULARS OF EMPLOYEES:

None of the employee of the company is drawing more than Rs. 1,02,00,000/- per annum or Rs. 8,50,000/- per month for the part of the year, during the year under review therefore Particulars of the employees as required under Section 197 of Companies Act, 2013 read with rule 5 (2) & rule 5 (3) of Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014 are not applicable, during the year under review.

31. VOTING RIGHTS OF EMPLOYEES:

During the year under review the company has not given loan to any employee for purchase of its own shares as per section 67(3)(c) of Companies Act, 2013. Therefore the company is not required to make disclosure as per Rule 6(4) of Companies (Share Capital and Debentures) Rules, 2014.

32. DISCLOSURE REGARDING ISSUE OF EMPLOYEE STOCK OPTIONS:

The Company has not issued shares under employee's stock options scheme pursuant to provisions of Section 62(1)(b) of Companies Act, 2013 read with Rule 12(9) of Companies (Share Capital and Debenture) Rules, 2014. So, question does not arise about voting rights not exercised by employee.

33. DISCLOSURE REGARDING ISSUE OF SWEAT EQUITY SHARES:

The Company does not have issued sweat equity shares pursuant to provisions of Section 54 of Companies Act, 2013 read with Rule 8 of Companies (Share Capital and Debenture Rules) 2014 during the Financial Year.

34. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

There was no case of sexual harassment reported during the year.

35. ACKNOWLEDGEMENT:

Your directors wish to place on records appreciation and acknowledge with gratitude the support, co-operation extended by Bankers, Employees and Shareholders including holding company.

For and on behalf of the Board of Directors
PUREGENE BIOTECH LIMITED

Place: - Indore

Date: - 24.05.2017

Harender Singh Bhatia
Director
DIN: 00509426

Kawaljeet Singh Bhatia
Director
DIN: 00401827

ANNEXURE I

FORM NO. MGT 9 EXTRACT OF ANNUAL RETURN

As on the financial year ended on 31st March, 2017

(Pursuant to Section 92 (3) of the Companies Act, 2013 and Rule 12(1) of the Company
(Management & Administration) Rules, 2014)

I. REGISTRATION & OTHER DETAILS:

1.	CIN	U01222MP1999PLC013303
2.	Registration Date	11-02-1999
3.	Name of the Company	PUREGENE BIOTECH LIMITED
4.	Category/Sub-category of the Company	Public Company Limited By Shares/Indian Non-government Company
5.	Address of the Registered office & contact details	1-B, Vikas Rekha Complex, Tower Square, Indore, Madhya Pradesh, 452001 Tel: 0731-4255900 Fax: 0731-4255949 E-mail: simranfarmscs@gmail.com
6.	Whether listed company (Yes/No)	No
7.	Name, Address & contact details of Registrar & Transfer Agent, if any.	Not Applicable (Being an unlisted company, the company do not have any Registrar & Transfer Agent)

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10 % or more of the total turnover of the company shall be stated

S. No.	Name and Description of main products/services	NIC Code of the Product/service	% to total turnover of the company
1	Raising of poultry (including broiler) and other domesticated birds; production of eggs and operation of poultry hatcheries	01222	Nil

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

Sr. No	Name and Address of the Company	CIN/GLN	Holding/ Subsidiary/ Associate	%age of Shares Held	Appli- cable Sections
1	Simran Farms Limited 1-B, Vikas Rekha Complex, Khatiwala Tank, Indore 452001 (M.P.)	L01222MP1984PLC002627	Holding Company	82.71	2(46)

g) FIIs	0	0	0	0	0	0	0	0	0
h) Foreign Venture Capital Funds	0	0	0	0	0	0	0	0	0
i) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(1):-	0	0	0	0	0	0	0	0	0
(2)Non- Institutions									
a) Bodies Corp.									
i) Indian	0	0	0	0	0	0	0	0	0
ii) Overseas	0	0	0	0	0	0	0	0	0
b) Individuals									
i) Individual shareholders holding nominal share capital up to Rs. 1 lakh	0	0	0	0	0	0	0	0	0
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	110000	110000	7.60	0	0	0	0	-7.60
c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	110000	110000	7.60	0	0	0	0	-7.60
Total Public share-holding (B)= (B)(1) +(B)(2)	0	110000	110000	7.60	0	0	0	0	-7.60
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	1446700	1446700	100.00	0	1446700	1446700	100.00	0

(B) SHAREHOLDING OF PROMOTERS

Sr. No	Shareholder's Name	Shareholding at the beginning of the year (As on 1 st April, 2016)			Shareholding at the end of the year (As on 31 st March, 2017)			%age change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged /encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged /encumbered to total shares	
1.	Gurdeep Singh Bhatia	100	0.01	0	100	0.01	0	0.00

2.	Sumeet Singh Bhatia	50	0.003	0	50	0.003	0	0.00
3.	Simran Farms Limited	1196500	82.71	0	1196500	82.71	0	0.00
4.	Kawaljeet Singh Bhatia	50	0.003	0	50	0.003	0	0.00
5.	Rajdeep Singh Bhatia	60000	4.15	0	0	0	0	-4.15
6.	Jasmiet Singh Bhatia	40000	2.76	0	0	0	0	-2.76
7.	Satbir Singh Bhatia	40000	2.76	0	0	0	0	-2.76
8.	Kawaljeet Kaur Bhatia	0	0	0	42000	2.90	0	2.90
9	Gurdeep Singh Bhatia (HUF)	0	0	0	41300	2.85	0	2.85
10	Gunjanpreet Kaur Bhatia	0	0	0	36700	2.54	0	2.54
11	Naampreet Kaur Bhatia	0	0	0	46649	3.22	0	3.22
12	Simrat Kaur Bhatia	0	0	0	41684	2.89	0	2.88
13	Jagdeep Kaur Bhatia	0	0	0	41667	2.89	0	2.88
	TOTAL	1336700	92.40	0	1446700	100.00	0	7.60

(C) CHANGE IN PROMOTERS' SHAREHOLDING (please specify, if there is no change)

Sr. No.	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
	At the beginning of the year	1336700	92.40	1336700	92.40
	Date wise Increase/Decrease in Promoters Shareholding during the year specifying the reasons for increase/decrease (e.g. allotment/ transfer/ bonus/sweat equity etc.) Reason: Transfer of shares on 31.10.2016	110000 (Details given below)	7.60	1446700	100.00
	At the end of the year	1446700	100.00	1446700	100.00

01	Rajdeep Singh Bhatia	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
	At the beginning of the year	60000	4.15	60000	4.15
	Transfer as on 31.10.2016	(60000)	(4.15)	0	0
	At the end of the year	0	0	0	0

02	Jasmiet Singh Bhatia	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
	At the beginning of the year	40000	2.76	40000	2.76
	Transfer as on 31.10.2016	(40000)	(2.76)	0	0
	At the end of the year	0	0	0	0

03	Satbir Singh Bhatia	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
	At the beginning of the year	40000	2.76	40000	2.76
	Transfer as on 31.10.2016	(40000)	(2.76)	0	0
	At the end of the year	0	0	0	0

04	Kawaljeet Kaur Bhatia	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
	At the beginning of the year	0	0	0	0
	Transfer as on 31.10.2016	42000	2.90	42000	2.90
	At the end of the year	42000	2.90	42000	2.90

05	Gurdeep Singh Bhatia (HUF)	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
	At the beginning of the year	0	0	0	0
	Transfer as on 31.10.2016	41300	2.85	41300	2.85
	At the end of the year	41300	2.85	41300	2.85

06	Gunjan Preet Kaur Bhatia	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
	At the beginning of the year	0	0	0	0
	Transfer as on 31.10.2016	36700	2.54	36700	2.54
	At the end of the year	36700	2.54	36700	2.54

07	Naampreet Kaur Bhatia	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
	At the beginning of the year	0	0	0	0
	Transfer as on 31.10.2016	46649	3.22	46649	3.22
	At the end of the year	46649	3.22	46649	3.22

08	Simrat Kaur Bhatia	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
	At the beginning of the year	0	0	0	0
	Transfer as on 31.10.2016	41684	2.89	41684	2.89
	At the end of the year	41684	2.89	41684	2.89

09	Jagdeep Kaur Bhatia	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
	At the beginning of the year	0	0	0	0
	Transfer as on 31.10.2016	41667	2.89	41667	2.89
	At the end of the year	41667	2.89	41667	2.89

**(D) SHAREHOLDING PATTERN OF TOP TEN SHAREHOLDERS
(Other than Directors, Promoters and Holders of GDRs and ADRs)**

Sl. No.	For Each of the Top 10 Shareholders	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	Parvinder Singh Gulyani				
	At the beginning of the year	60000	4.15%	60000	4.15%
	Date wise Increase/Decrease in Share holding during the year specifying the reasons for increase/decrease (e.g. allotment/transfer/bonus/sweat equity etc)	(60000) Transfer of Shares as on 31.10.2016	(4.15%)	0	0
	At the End of the year (or on the date of separation, if separated during the year)	0	0	0	0

Sl. No.	For Each of the Top 10 Shareholders	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
2	Gurdeep Singh Tuteja				
	At the beginning of the year	50000	3.46%	50000	3.46%

	Date wise Increase/Decrease in Share holding during the year specifying the reasons for increase/ decrease (e.g. allotment/transfer/ bonus/sweat equity etc)	(50000) Transfer of Shares as on 31.10.2016	(3.46%)	0	0
	At the End of the year (or on the date of separation, if separated during the year)	0	0	0	0

* Board of Directors in their Board Meeting held on 31.10.2016 approved the transfer of Shares.

(E) SHAREHOLDING OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

Sr. No.	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
01	Harender Singh Bhatia (Director)				
	At the beginning of the year	0	0.00	0	0.00
	Date wise Increase/Decrease in Share holding during the year specifying the reasons for increase/ decrease (e.g. allotment /transfer/bonus/sweat equity etc)	0	0.00	0	0.00
	At the End of the year	0	0.00	0	0.00

Sr. No.	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
02	Kawaljeet Singh Bhatia (Director)				
	At the beginning of the year	50	0.003	50	0.003
	Date wise Increase/Decrease in Share holding during the year specifying the reasons for increase/decrease (e.g. allotment /transfer/bonus/sweat equity etc)	0	0.00	50	0.003
	At the End of the year	50	0.003	50	0.003

Sr. No.	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	%age of total shares of the company	No. of shares	%age of total shares of the company
03	Gurmeet Singh Bhatia (Director)				
	At the beginning of the year	0	0.00	0	0.00

Date wise Increase/Decrease in Share holding during the year specifying the reasons for increase/decrease (e.g. allotment/transfer/bonus/sweat equity etc):	0	0.00	0	0.00
At the End of the year	0	0.00	0	0.00

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

(Rs. in Lakhs)

Particulars	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year	-	-	-	-
i) Principal Amount	-	-	-	-
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	-	-	-	-
Change in Indebtedness during the financial year				
* Addition	-	-	-	-
* Reduction	-	-	-	-
Net Change	-	-	-	-
Indebtedness at the end of the financial year	-	-	-	-
i) Principal Amount	-	-	-	-
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	-	-	-	-

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

A) Remuneration to Managing Director, Whole-time Directors and/or Manager (Company not appointed MD, WTD and Manager)

Sl. No.	Particulars of Remuneration	Name of MD/WTD/ Manager	Total Amount
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961		
2.	Stock Option		
3.	Sweat Equity		
4.	Commission - as % of profit - others, specify.		
5.	Others, please specify		
	Total (A)		
	Ceiling as per the Act		

B) Remuneration to other directors:

Sl. no.	Particulars of Remuneration	Name of Directors			Total Amount
		Harender Singh Bhatia	Kawaljeet Singh Bhatia	Gurmeet Singh Bhatia	
	1. Independent Directors · Fee for attending board committee meetings · Commission · Others, please specify	0	0	0	0
	Total (1)	0	0	0	0
	2. Other Non-Executive Directors · Fee for attending board committee meetings · Commission · Others, please specify	0	0	0	0
	Total (2)	0	0	0	0
	Total (B)=(1+2)	0	0	0	0
	Total Managerial Remuneration	0	0	0	0
	Overall Ceiling as per the Act	0	0	0	0

C) Remuneration to Key Managerial Personnel other than MD/Manager/WTD: **(Not Appointed)**

Sl.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company	CFO	Total
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961				
2.	Stock Option				
3.	Sweat Equity				
4.	Commission - as % of profit - Others, specify...				
5.	Others, please specify				
	Total				

VII. PENALTIES / PUNISHMENT / COMPOUNDING OF OFFENCES: Nil

For and on behalf of the Board of Directors
PUREGENE BIOTECH LIMITED

Place: - Indore
Date: - 24.05.2017

Harender Singh Bhatia
Director
DIN: 00509426

Kawaljeet Singh Bhatia
Director
DIN: 00401827

ANNEXURE-II

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.		Details
(a)	Name(s) of the related party & nature of relationship	Nil
(b)	Nature of contracts/arrangements/transaction	Nil
(c)	Duration of the contracts/arrangements/transaction	Nil
(d)	Salient terms of the contracts or arrangements or transaction including the value, if any	Nil
(e)	Justification for entering into such contracts or arrangements or transactions'	Nil
(f)	Date(s) of approval by the Board	Nil
(g)	Amount paid as advances, if any	Nil
(h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	Nil

2. Details of Material contracts or arrangements or transactions at Arm's length basis		Details
(a)	Name(s) of the related party & nature of relationship	Simran Farms Limited (Holding Company)
(b)	Nature of contracts/arrangements/transaction	Rent & Rearing Charges
(c)	Duration of the contracts/arrangements/transaction	Yearly
(d)	Salient terms of the contracts or arrangements or transaction including the value, if any	Rs 54.00 lacs
(e)	Date(s) of approval by the Board	As all the related party transactions are on arm's length basis and in the ordinary course of business, therefore Board's approval is not required.
(f)	Amount paid as advances or refunded, if any	Nil

For and on behalf of the Board of Directors
PUREGENE BIOTECH LIMITED

Place: - Indore
Date: - 24.05.2017

Harender Singh Bhatia
Director
DIN: 00509426

Kawaljeet Singh Bhatia
Director
DIN: 00401827

INDEPENDENT AUDITOR'S REPORT

To the Members of Puregene Biotech Limited,

Report on the Standalone Financial Statements

We have audited the accompanying standalone financial statements of **Puregene Biotech Limited** ('the Company'), which comprise the balance sheet as at 31 March 2017, the statement of profit and loss and the cash flow statement for the year then ended, and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2017 and its profit and its cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, we give in the annexure A, a statement on the matters specified in the paragraph 3 & 4 of the order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) the balance sheet, the statement of profit and loss and the cash flow statement dealt with by this Report are in agreement with the books of accounts.
 - (d) in our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (e) on the basis of the written representations received from the directors as on 31 March, 2017 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March, 2017 from being appointed as a director in terms of Section 164(2) of the Act.
 - (f) with respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B", and
 - (g) with respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long term contracts including derivative contracts for which there were any foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company, and its subsidiary companies, incorporated in India.

iv. The company has no Specified Bank Notes (SBNs) as on 8th November, 2016 hence the disclosure regarding the same is not applicable.

For, Khandelwal Kakani & Co.

Chartered Accountants

FRN No.: 001311C

CA Santosh Deshmukh

Partner

M. No.: 071011

Place: Indore

Date: 24th May, 2017

Annexure A to the Auditors Report

The Annexure referred to in our Independent Auditor's Report to the members of Puregene Biotech Limited on the standalone financial statements for the year ended 31 March 2017, we report that:

1. In respect of fixed assets:

- a. The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - b. The Management has physically verified the Fixed Assets at Reasonable Intervals during the year & on the basis of explanations given to us, no discrepancies were noticed on such verification.
 - c. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties are held in the name of the Company.
2. In View of Arrangement of rearing & lease with Parent Company, the company has not held any inventory throughout the year hence clause of physical verification is not applicable.
 3. The Company has not granted any loan to any company, firms or other party covered under section 189 of the Companies Act, 2013.
 4. In our opinion and according to the information and explanations given to us, the company is not advances any loans, made investments, gave guarantees, and provided security prescribed in provisions of section 185 and 186 of the Companies Act, 2013. Thus, paragraph (4) of the Order is not applicable to the Company.
 5. The Company has not accepted any deposits from public and hence this clause is not applicable.
 6. The Central Government has not prescribed the maintenance of cost records under section 148(1) of the Act, for any of the services rendered by the Company.
 7. (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted / accrued in the books of account in respect of undisputed statutory dues including provident fund, income tax, sales tax, service tax, value added tax, cess and other material statutory dues have been regularly deposited during the year by the Company with the appropriate authorities.

(b) According to the information and explanations given to us and on the basis of examination of records of the company there is no dispute in respect income tax or sales tax or service tax or value added tax.
 8. The Company has not defaulted in repayment of loans or borrowing to a bank. Also company has not taken any loans or borrowings from Government or debenture holders. Accordingly, paragraph 3(viii) of the Order is not applicable.
 9. The Company did not raise any money by way of initial public offer or further public offer (including debt instruments). The Company raise the term loans during the year for purchasing the vehicles the same are applied for the purpose for which those are raised.
 10. According to the information and explanations given to us, no fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
 11. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.

12. In our opinion and according to the information and explanations given to us, the Company is not a nidhi company. Accordingly, paragraph 3(xii) of the Order is not applicable.
13. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
14. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
15. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Order is not applicable.
16. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

For, KHANDELWAL KAKANI & CO.

Chartered Accountants

FRN: 001311C

CA SANTOSH DESHMUKH

M. No.: 071011

Partner

Place: Indore

Date: 24th May, 2017

Annexure - B to the Auditors' Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **Puregene Biotech Limited** ("the Company") as of 31 March 2017 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Puregene Biotech Limited

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2017, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For: Khandelwal Kakani & Co.

Chartered Accountants

FRN No.: 001311C

CA Santosh Deshmukh

Partner

M. No. : 071011

Place: Indore

Date: 24th May 2017

Puregene Biotech Limited

PUREGENE BIOTECH LIMITED BALANCE SHEET AS AT 31 March, 2017

(Rs. In Lakhs)

Particulars	Note	31-Mar-17	31-Mar-16
A EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital	1	144.67	144.67
(b) Reserves and surplus	2	49.71	39.75
		<u>194.38</u>	<u>184.42</u>
2 Current liabilities			
(a) Trade payables	3	0.00	1.79
(b) Short-term provisions	4	6.88	7.64
		<u>6.88</u>	<u>9.43</u>
		201.26	193.85
B ASSETS			
1 Non-current assets			
(a) Fixed assets			
(i) Tangible assets	5	117.57	126.45
(b) Deferred tax assets (net)	6	2.76	2.76
(c) Long term loans and advances	7	1.06	1.06
		<u>121.40</u>	<u>130.28</u>
2. Current assets			
(a) Trade receivable	8	70.05	49.10
(b) Cash and bank balances	9	0.83	2.27
(c) Short-term loans and advances	10	8.99	12.20
		<u>79.87</u>	<u>63.57</u>
		201.26	193.85

See accompanying notes forming part of the financial statement

In terms of our report attached.

FOR KHANDELWAL KAKANI & CO.

Chartered Accountants

FRN: 001311C

CA SANTOSH DESHMUKH

PARTNER

(M. No. 071011)

Place: Indore

Date: 24th May 2017

H.S. BHATIA

Director

DIN: 00509426

K.S. BHATIA

Director

DIN: 00401827

Puregene Biotech Limited

PUREGENE BIOTECH LIMITED PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31 March, 2017

(Rs. In Lakhs except EPS)

Particulars	Note	31 March, 2017	31 March, 2016
Other income	11	54.00	54.00
Total revenue		54.00	54.00
Expenses			
(a) Farm expenses	12	9.55	9.49
(b) Administrative expenses	13	0.68	0.53
(c) Selling & distribution expenses	14	0.07	0.17
(d) Employee benefits expense	15	18.54	18.48
(e) Finance costs	16	0.19	0.13
(f) Depreciation	5	8.88	9.01
Total expenses		37.91	37.81
Profit / (Loss) before tax		16.09	16.19
Tax expense:			
(a) Current tax expense for current year		6.13	5.96
(b) Deferred tax		0.00	0.00
Add:- MAT Credit		0.00	0.00
Profit / (Loss) for the year		9.97	10.23
Earnings per share (of Rs. 10/ each)			
Basic and diluted	17	0.69	0.71
See accompanying notes forming part of the financial statement			

In terms of our report attached.

FOR KHANDELWAL KAKANI & CO.
Chartered Accountants
FRN: 001311C

CA SANTOSH DESHMUKH
PARTNER

H.S. BHATIA
Director
DIN: 00509426

K.S. BHATIA
Director
DIN: 00401827

Place: Indore
Date: 24th May 2017

Puregene Biotech Limited

PUREGENE BIOTECH LIMITED CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2017

		(Rs.In Lakhs)	
Particulars		As at 31.03.2017	As at 31.03.2016
A.	CASH FLOW FROM OPERATING ACTIVITIES:		
	NET PROFIT BEFORE TAX & EXTRA ORDINARY ITEM	16.09	16.19
	Adjustment to reconcile profit before tax to cash generated by operating activities		
Add:	Depreciation	8.88	9.01
	Interest paid	0.00	0.13
	Operating Profit before working capital change	24.97	25.33
Add:	Short Term Loans & Advances	0.57	0.00
	Trade Payable	0.00	1.79
	Short Term Provisions	0.00	0.21
Less:	Short Term Provisions	0.93	0.00
	Trade Payable	1.79	0.00
	Trade Receivable	20.95	5.58
	Short Term Loans & Advances	0.00	0.46
	Operating profit after working capital change	1.87	21.29
Less:	Income tax paid	3.31	2.60
	Operating profit before charging Extra Ordinary Items	(1.44)	18.69
Add:	Extra ordinary Item	0.00	0.00
	Net Cash inflow from operating activities	(1.44)	18.69
	A		
B.	CASH FLOW FROM INVESTING ACTIVITIES		
	Deposits	0.00	0.00
	Net Cash inflow from Investing Activities	0.00	0.00
	B		
C.	CASH FLOW FROM FINANCIAL ACTIVITIES		
Less:	Repayment of Loan		
	Interest paid on late payment	0.00	0.03
	Term Loan	0.00	20.00
	Net Cash Flow from financial activities	0.00	(20.03)
	C		
	NET INCREASE IN CASH & CASH EQUIVALENTS	(1.44)	(1.34)
	(A+B+C)		
Add:	CASH & CASH EQUIVALENTS AT THE BEGINNING OF PERIOD	2.27	3.61
	CASH & CASH EQUIVALENTS AT THE END OF PERIOD	0.83	2.27

Puregene Biotech Limited

Notes on Financial Statement for the Year ended 31st March 2017

(Rs. In Lakhs)

Particulars	As at			
	31-Mar-17	31-Mar-16		
1 Share Capital				
(a) Authorised				
15,00,000 Equity shares of Rs.10/ each	150.00	150.00		
(b) Issued, Subscribed and Paid Up				
1446700 Equity Shares of Rs. 10/- each	144.67	144.67		
The details of shareholders holding more than 5 % shares :-				
Name of Shareholder	31-Mar-17		31-Mar-16	
	No. of Shares	% Held	No. of Shares	% Held
Simran Farms Limited	1196500	82.71%	1196500	82.71%
2 Reserve and Surplus				
a. Surplus				
Opening balance	39.75		29.52	
Less:- Opening Retain Earning Depreciation	0.00		0.00	
(+) Net Profit/(Net Loss) For the current year	9.97		10.23	
Closing Balance	49.71		39.75	
3 Trade Payables				
Outstanding less than six months	0.00		1.79	
	0.00		1.79	
4 Short term provisions				
(a) Provision for employee benefits				
Salary payable	0.00		0.91	
Contribution to PF (Company)	0.11		0.13	
Contribution to PF (Staff)	0.10		0.12	
(b) Provisions Others				
Other payable	0.42		0.27	
Income Tax Payable	6.13		5.96	
Audit fees provision	0.12		0.24	
	6.88		7.64	
6 Deferred tax liabilities/Assets				
Opening Deferred tax assets	2.76		2.76	
(a) Deferred tax liabilities on account of:				
(i) Depreciation	0.00		0.00	
(ii) DTA reversal on account of diff. in Profit as per Co. Act & IT Act	0.00		0.00	
Closing deferred tax assets	2.76		2.76	
7 Long term loans and advances				
(Unsecured Considered goods)				
MPEB deposit	1.06		1.06	
	1.06		1.06	

NOTE: During the year there is no creation of deferred tax asset on difference of depreciation on account of para-15 of "AS-22" Accounting for taxes on income. In view of para 15 of AS-22, Deferred tax assets should be recognised and carried forward only to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be recognised.

PUREGENE BIOTECH LIMITED

Notes on Financial Statement for the year ended on 31st March 2017

Note - 05**(Rs. In Lakhs)**

Fixed Assets	Gross Block				Accumulated Depreciation					Net Block	
Particulars	Balance as at April 1 2016	Additions During the year	Sales/ Deduction	Balance as at 31 March 2017	Balance as at April 1 2016	Depreciation for the year	Depreciation Charged from retain earning	Deduction during the year	Balance as at 31 March 2017	Balance as at 1 April 2016	Balance as at 31 March 2017
Tangible Assets											
Land	21.94	0.00	0.00	21.94	0.00	0.00	0.00	0.00	0.00	21.94	21.94
Buildings (Factory)	170.68	0.00	0.00	170.68	87.08	5.09	0.00	0.00	92.17	83.60	78.52
Poultry Equipment	44.17	0.00	0.00	44.17	25.67	2.60	0.00	0.00	28.27	18.51	15.90
Poultry Equipment (R& D)	9.66	0.00	0.00	9.66	7.85	1.18	0.00	0.00	9.03	1.81	0.63
Furniture and Fixtures	0.42	0.00	0.00	0.42	0.38	0.01	0.00	0.00	0.39	0.04	0.03
Electrical Installation	0.25	0.00	0.00	0.25	0.24	0.00	0.05	0.00	0.24	0.01	0.01
Tubewell & Land Development	10.66	0.00	0.00	10.66	10.13	0.00	0.00	0.00	10.13	0.53	0.53
Total	257.80	0.00	0.00	257.80	131.35	8.88	0.00	0.00	140.23	126.45	117.57
Previous Year	257.80	0.00	0.00	257.80	122.34	9.01	0.00	0.00	131.35	135.46	126.45

Puregene Biotech Limited

Notes on Financial Statement for the Year ended 31st March 2017

(Rs. In Lakhs)

		As at	
Particulars	31-Mar-17	31-Mar-16	
8 Trade receivable			
Simran farms limited	70.05	49.10	
	70.05	49.10	
9 Cash and bank balances			
(a) Cash on hand			
Cash on hand	0.40	0.25	
(c) Balances with banks			
(i) In current accounts			
ICICI Bank, Indore	0.42	2.02	
	0.83	2.27	
10 Short term loan and advances			
(Unsecured Considered goods)			
TDS deducted from us	1.80	1.80	
Advance income tax	0.90	0.75	
MAT Credit Entitlement	6.29	9.08	
Advances recoverable in cash or in kind or for value to be received	0.00	0.57	
	8.99	12.20	
11 Other Income			
Rent recd. (building)	9.00	9.00	
Rearing charges (Income)	45.00	45.00	
	54.00	54.00	
12 Farm expenses			
Expenses at Farm	4.21	3.25	
Power & Energy / Light water	5.35	6.24	
	9.55	9.49	
13 Administrative expenses			
General Office Expenses	0.34	0.19	
Audit Fees (Refer Pt. 20)	0.12	0.12	
Legal & Professional Expenses	0.22	0.22	
	0.68	0.53	
14 Selling and distribution Exp.			
Vehicle Repair & Maintenance	0.07	0.17	
	0.07	0.17	
15 Employee benefits expense			
Salary wages & Bonus	17.00	16.82	
Provident fund contribution	1.54	1.66	
	18.54	18.48	
16 Finance cost			
Bank Charges & Commission	0.00	0.03	
Interest on late payment	0.19	0.10	
	0.19	0.13	
17 Earnings Per Share			

Basic & Diluted earning per equity share are recorded in accordance with AS-20 "Earnings Per Share". Basic and diluted earnings per equity share are calculated by dividing Net profit after tax of Rs. 9.97 lacs by 1446700 equity shares (Face value of Rs.10/- each)

Puregene Biotech Limited

Notes on Financial Statement for the Year ended 31st March 2017

18 Related Party Disclosures

- (1) Relationship
- (a) Holding Companies
Simran Farms Ltd.
- (b) Key Management personnel:
Mr. Harendar Singh Bhatia
Director
Mr. Gurmeet Singh Bhatia
Director
Mr. Kawaljeet Singh Bhatia
Director

Note: Related party relationship is as identified by the Company and relied upon by the Auditors

- (2) Transactions carried out with related parties referred to 1 above, in ordinary course of business:

Nature of Transaction	Referred in 1(a) above	Referred in 1(b) above
Purchase	0.00	
Sales	0.00	
Lease rent/Rent	9.00	
Rearing Charge	45.00	
Finance	0.00	
Outstanding	0.00	
Payable	0.00	
Receivable	70.05	

19 Payment to Auditors	2016-17	2015-16
(i) As Auditors	0.12	0.12
	0.12	0.12

20. Disclosure under Micro, Small & Medium Scale Enterprise Development Act, 2006

The Company has no outstanding balance as on 31.03.2017. Hence provision of Micro, Small & Medium Enterprises Act 2006 is not applicable.

21. In the opinion of the Board of Directors, Fixed Assets, Current Assets, Loans & Advances are approximately of the value as stated, if realized in the ordinary course of business except otherwise specified. The provisions for all known liabilities are adequate and not in excess of the amount which is reasonably necessary.
22. As per information given by the management, Excise Duty is not applicable to the company.

Puregene Biotech Limited

1. SIGNIFICANT ACCOUNTING POLICIES:

A) Basis of preparation of Financial Statements:

(a) Method of Accounting

The Company maintains its accounts on accrual basis except insurance claims and claims on Parent Birds, Commercial Birds & Hatching eggs, sale of manure and gunny bags which are accounted on cash basis.

(b) Classification under Companies Act, 2013

The Company is a Non-Small and Medium sized Company (Non SMC) as defined in the general instructions in respect of accounting standards as notified by the Companies (Accounting Standards) Rules, 2006.

B) Use of estimate:

The Preparation of financial statement in conformity with generally accepted accounting principles require estimate and assumption to be made that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities on the date of financial statement and the reported amounts of revenues and expenses during the reporting period, actual results could be differ from these estimates and difference between actual result and estimate are recognised in the period in which the results are known/materialize.

C) Cash flow statement:

The cash flow statement is prepared using the "Indirect method set out in Accounting Standard 3 "Cash Flow Statement" which presents cash flow from operating, investing and financing activities of the company.

D) Fixed Assets

- i) Fixed Assets are stated at cost of acquisition less accumulated depreciation, impairment loss, & is inclusive of duties, taxes, incidental expenses, erection / commissioning expenses, till the date of commencement of production and all necessary expenses to bring the asset to its working condition.
- ii) Capital Work in Progress comprises the cost of Fixed Asset that are yet not ready for their intended use at the Balance Sheet date.

E) Depreciation:

Depreciation is provided on the basis of straight line method over useful life of the assets as prescribed in Schedule-II to the Companies Act, 2013.

F) Revenue Recognition:

- i) Revenues from sale of goods are recognised when risks and rewards of ownership of goods are passed on to the customers, which are generally on dispatch of goods and are recorded net of taxes and duties.
- ii) Income from services are recognised on prorata basis i.e. as and when services are rendered.

G) Investment:

Investments are classified as Current Investments and Long Term Investments based on intention of the management at the time of purchase. Current investments are stated at the lower of the cost and fair value and long term investments are stated at cost.

H) Retirement / Post Retirement Benefits:

The company provides retirement benefits in the form of gratuity and leave encashment. In view of Companies employees turnover due to resignation during the year, the accounts of the employees for gratuity and leave encashment have been already settled and there is no liability as on 31.03.2017 towards employee's retirement benefits who have joined during the year hence not provided.

Puregene Biotech Limited

I) Borrowing Cost:

Borrowing cost that are directly attributable to the acquisition, Construction or production of the qualifying assets are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily take substantial period of time to get ready for intended use. All other borrowing cost are charged to the statement of profit and loss account.

J) Operating lease

Lease arrangements where risks and rewards incidental to the ownership of an asset substantially vest with lessor are classified as operating lease. Rental income on assets given and rental expense on assets obtained under operating lease arrangements are recognised in the statement of profit and loss for the year as per the terms and conditions of the respective lease agreement.

K) Earning Per Share:

Basic & Diluted earning per equity share are recorded in accordance with AS-20 "Earnings Per Share". Earnings per equity share are calculated by dividing Net profit attributable to the equity shareholder by weighted average number of equity shares outstanding during the year.

L) Taxes on income:

- 1) Tax expenses for a year comprises of current tax and Deferred tax.
- 2) Tax on income for the current year is determined on the basis of the taxable income and tax Credits computed in accordance with the provision of Income Tax Act, 1961, and based in Expected outcome of Assessments/Appeals
- 3) Deferred Tax is recognized on timing difference between the accounting income and the taxable income for the year and quantified using the tax rates and laws enacted or substantively enacted as on the balance sheet date. Deferred tax assets are recognised and carried forward to the extent there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.
- 4) Minimum alternate Tax (MAT) credit is recognised as an asset only when and to the extent there is convincing evidence that the company will pay income tax higher than the computed under MAT, during the period under which MAT is permitted to be set off under applicable laws.
- 5) In the year in which MAT credit become eligible to be recognised as an asset in accordance with recommendation contained in the guidance Note issued by the Chartered Accountants of India (ICAI), the said asset is created by way of a credit to the statement of profit and loss and shown as MAT credit entitlement. The company reviews the same at each Balance sheet date and writes down the carrying Amount of MAT credit entitlement to the extent there is longer convincing evidence to the effect that company will pay Income tax higher than MAT during the specified period.

M) Research and Development:

Revenue expenditure on research and development is charged to Statement of Profit and loss for the year.

N) Provisions, Contingent Liabilities and contingent assets:

1) PROVISIONS

Provision is recognized in the accounts when there is a present obligation as a result of past event(s) and it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

2) CONTINGENT LIABILITIES

A contingent liability is a possible obligation that arise from past event whose existence will be confirmed by the occurrence or non occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare case where there is a liability that cannot be recognized because it cannot be

Puregene Biotech Limited

measured reliably. The company does not recognize contingent liabilities but discloses its existence in the financial statements.

3) CONTINGNT ASSETS

Contingent Assets are neither recognized nor disclosed in the financial statements.

0) Cash & Cash Equivalentents

Cash & cash equivalentents for the purpose of Cash Flow Statement comprises of Cash at Bank & Cash on Hand and Fixed Deposits in bank with original maturity less than three months.